Team members:

• Ferran Sanz
• Laura Furlong
• Janet Piñero
• Alexia Giannoula
• Àlex Bravo
• Núria Queralt-Rosinach
• Miguel A. Mayer
• Alba Gutiérrez-Sacristán

Contact email:
[email protected]
[email protected]

Research Programme on Biomedical Informatics, Research Group on Integrative Biomedical Informatics
(PSMAR-IMIM) – Barcelona, Spain
<

The Research Programme of Biomedical Informatics (GRIB) is a joint programme of both the IMIM and the Universitat Pompeu Fabra (UPF), which is located at the Barcelona Biomedical Research Park (PRBB). GRIB carries out fundamental research and technological developments on the application of advanced information technologies and computational methods in the health and life sciences. GRIB brings together a multidisciplinary team of more than 60 scientists, as well as technical and management staff. It has a wide experience in coordinating and participating in research projects funded by the European Commission and other research funding agencies. GRIB has a long tradition of collaboration with the pharmaceutical and biotechnological industry. GRIB is the node for Biomedical Informatics of the Spanish Institute of Bioinformatics (INB), and it is endorsed and funded by the Catalan Government as one of the centres of TECNIO, the Catalan Technological Innovation Network. The research activity of GRIB has originated the creation of several spin-off companies such as Pharmatools Interactive Services, Chemotargets and Acellera.
In particular, the GRIB participation in the MedBioinformatics project will be carried out through its research group on Integrative Biomedical Informatics (IBI). The goal of IBI is to develop computational methods and tools for facilitating the integrative exploitation of the wealth of information generated in biomedical research and clinical practice.
The current research lines of the IBI are:

• Development of new strategies and tools for knowledge extraction from biomedical literature and other publicly available resources.
• Network biology for the study of human diseases and drug safety.
• Development and application of innovative approaches to exploit clinical data for research.
• Integrative knowledge management and exploitation in drug discovery and development, including multi-level and multi-scale modelling and simulation.